

- 29 Mulders MN, Venard V, Njayou M *et al.* Low genetic diversity despite hyperendemicity of hepatitis B virus genotype E throughout West Africa. *J Infect Dis* 2004; 190: 400–8.
- 30 Ayed K, Gorgi Y, Ayed-Jendoubi S *et al.* Hepatitis B virus genotypes and precore/core-promoter mutations in Tunisian patients with chronic hepatitis B virus infection. *J Infect* 2007; 54: 291–7.
- 31 Borchani-Chabchoub I, Gargouri A, Mokdad-Gargouri R. Genotyping of Tunisian hepatitis B virus isolates based on the sequencing of preS2 and S regions. *Microbes Infect* 2000; 2: 607–12.
- 32 Saady N, Sugauchi F, Tanaka Y *et al.* Genotypes and phylogenetic characterization of hepatitis B and delta viruses in Egypt. *J Med Virol* 2003; 70: 529–36.
- 33 Zekri AR, Hafez MM, Mohamed NI *et al.* Hepatitis B virus (HBV) genotypes in Egyptian pediatric cancer patients with acute and chronic active HBV infection. *Virology* 2007; 4: 74.
- 34 Ezzikouri S, Chemin I, Chafik A *et al.* Genotype determination in Moroccan hepatitis B chronic carriers. *Infect Genet Evol* 2008; 8: 306–12.
- 35 Amini-Bavil-Olyaei S, Sarrami-Forooshani R, Adeli A *et al.* Complete genomic sequence and phylogenetic relatedness of hepatitis B virus isolates from Iran. *J Med Virol* 2005; 76: 318–26.
- 36 Amini-Bavil-Olyaei S, Sarrami-Forooshani R, Mahboudi F *et al.* Genotype characterization and phylogenetic analysis of hepatitis B virus isolates from Iranian patients. *J Med Virol* 2005; 75: 227–34.
- 37 Sendi H, Mehrab-Mohseni M, Zali MR, Norder H, Magnus LO. T1764G1766 core promoter double mutants are restricted to Hepatitis B virus strains with an A1757 and are common in genotype D. *J Gen Virol* 2005; 86: 2451–8.
- 38 Mojiri A, Behzad-Behbahani A, Saberifirozi M *et al.* Hepatitis B virus genotypes in southwest Iran: molecular, serological and clinical outcomes. *World J Gastroenterol* 2008; 14: 1510–13.
- 39 Alavian SM, Keyvani H, Rezai M, Ashayeri N, Sadeghi HM. Preliminary report of hepatitis B virus genotype prevalence in Iran. *World J Gastroenterol* 2006; 12: 5211–13.
- 40 Moradi A, Kazeminejad V, Roshandel G, Kalavi K, Ghaemi EO, Semnani S. Hepatitis B virus genotypes in Iran. *Indian J Med Sci* 2008; 62: 204–5.
- 41 Ben-Ari Z, Daudi N, Klein A *et al.* Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. *Am J Gastroenterol* 2003; 98: 151–9.
- 42 Ben-Ari Z, Ashur Y, Daudi N *et al.* Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation. *Clin Transplant* 2004; 18: 415–22.
- 43 El-Zaatari M, Kazma H, Naboulsi-Majzoub M *et al.* Hepatitis B virus DNA in serum of "anti-HBc only"-positive healthy Lebanese blood donors: significance and possible implications. *J Hosp Infect* 2007; 66: 278–82.
- 44 Sharara AI, Ramia S, Ramlawi F *et al.* Prevalence of restriction fragment length polymorphism patterns of hepatitis B virus compatible with genotype D in Lebanon. *Eur J Clin Microbiol Infect Dis* 2004; 23: 861–3.
- 45 Hajeer AH, Al Knawy B, Alhaj-Hussein BT, Al-Rubiaan SD. Hepatitis B virus: a study of genotypes in an infected Saudi cohort. *Br J Biomed Sci* 2007; 64: 93–4.
- 46 Bozdayi G, Turkyilmaz AR, Idilman R *et al.* Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from Turkish patients with chronic HBV infection. *J Med Virol* 2005; 76: 476–81.
- 47 Pinarbasi B, Onel D, Cosan F *et al.* Prevalence and virological features of occult hepatitis B virus infection in female sex workers who work uncontrolled in Turkey. *Liver Int* 2008; 29: 227–30.
- 48 Senturker Guldaz N, Abacioglu YH. S-gene sequences and genotype-related restriction sites in hepatitis B virus carriers in Turkey. *Infection* 2004; 32: 344–9.
- 49 Ozaslan M, Ozaslan E, Barsgan A, Koruk M. Mutations in the S gene region of hepatitis B virus genotype D in Turkish patients. *J Genet* 2007; 86: 195–201.
- 50 Serin MS, Akkiz H, Abayli B, Oksuz M, Aslan G, Emekdas G. Genotyping of hepatitis B virus isolated from chronic hepatitis B patients in the south of Turkey by DNA cycle-sequencing method. *Diagn Microbiol Infect Dis* 2005; 53: 57–60.
- 51 Ozdemir FT, Duman D, Ertem D *et al.* Determination of hepatitis B genotypes in patients with chronic hepatitis B virus infection in Turkey. *Turk J Gastroenterol* 2005; 16: 183–7.
- 52 Bozdayi AM, Bozkaya H, Turkyilmaz AR *et al.* Nucleotide divergences in the core promoter and precore region of genotype D hepatitis B virus in patients with persistently elevated or normal ALT levels. *J Clin Virol* 2001; 21: 91–101.
- 53 Sayiner AA, Ozcan A, Sengonul A. Naturally occurring MHR variants in Turkish patients infected with hepatitis B virus. *J Med Virol* 2008; 80: 405–10.
- 54 Sunbul M, Leblebicioglu H. Distribution of hepatitis B virus genotypes in patients with chronic hepatitis B in Turkey. *World J Gastroenterol* 2005; 11: 1976–80.
- 55 Kaya S, Cetin ES, Aridogan BC, Onal S, Demirci M. Distribution of hepatitis B virus (HBV) genotypes among HBV carriers in Isparta. *Iran Biomed J* 2007; 11: 59–63.
- 56 Aksoy A, Ozdarendeli A. [Genotyping of hepatitis B virus by restriction enzyme analysis]. *Mikrobiyol Bul* 2006; 40: 215–23.
- 57 Leblebicioglu H, Eroglu C. Acute hepatitis B virus infection in Turkey: epidemiology and genotype distribution. *Clin Microbiol Infect* 2004; 10: 537–41.

- 58 Sallam TA, William Tong CY. African links and hepatitis B virus genotypes in the Republic of Yemen. *J Med Virol* 2004; 73: 23–8.
- 59 Khan A, Kurbanov F, Tanaka Y *et al.* Epidemiological and clinical evaluation of hepatitis B, hepatitis C, and delta hepatitis viruses in Tajikistan. *J Med Virol* 2008; 80: 268–76.
- 60 Kato H, Ruzibakiev R, Yuldasheva N *et al.* Hepatitis B virus genotypes in Uzbekistan and validity of two different systems for genotyping. *J Med Virol* 2002; 67: 477–83.
- 61 Avazova D, Kurbanov F, Tanaka Y *et al.* Hepatitis B virus transmission pattern and vaccination efficiency in Uzbekistan. *J Med Virol* 2008; 80: 217–24.
- 62 Amini-Bavil-Olyae S, Alavian SM, Adeli A *et al.* Hepatitis B virus genotyping, core promoter, and precore/core mutations among Afghan patients infected with hepatitis B: a preliminary report. *J Med Virol* 2006; 78: 358–64.
- 63 Kumar M, Sarin SK, Hissar S *et al.* Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. *Gastroenterology* 2008; 134: 1376–84.
- 64 Borkakoty BJ, Mahanta J, Biswas D. Circulating genotypes of hepatitis B virus in Arunachal Pradesh. *Indian J Med Res* 2008; 127: 65–70.
- 65 Gandhe SS, Chadha MS, Arankalle VA. Hepatitis B virus genotypes and serotypes in western India: lack of clinical significance. *J Med Virol* 2003; 69: 324–30.
- 66 Chattopadhyay S, Das BC, Hussain Z, Kar P. Hepatitis B virus genotypes in acute and fulminant hepatitis patients from north India using two different molecular genotyping approaches. *Hepatol Res* 2006; 35: 79–82.
- 67 Chandra PK, Banerjee A, Datta S, Chakravarty R. G1862T mutation among hepatitis B virus-infected individuals: association with viral genotypes and disease outcome in Kolkata, Eastern India. *Intervirology* 2007; 50: 173–80.
- 68 Biswas A, Chandra PK, Datta S *et al.* Frequency and distribution of hepatitis B virus genotypes among eastern Indian voluntary blood donors: association with precore and basal core promoter mutations. *Hepatol Res* 2009; 39: 53–9.
- 69 Chattopadhyay S, Das BC, Kar P. Hepatitis B virus genotypes in chronic liver disease patients from New Delhi, India. *World J Gastroenterol* 2006; 12: 6702–6.
- 70 Vivekanandan P, Abraham P, Sridharan G *et al.* Distribution of hepatitis B virus genotypes in blood donors and chronically infected patients in a tertiary care hospital in southern India. *Clin Infect Dis* 2004; 38: e81–6.
- 71 Chowdhury A, Santra A, Chakravorty R *et al.* Community-based epidemiology of hepatitis B virus infection in West Bengal, India: prevalence of hepatitis B e antigen-negative infection and associated viral variants. *J Gastroenterol Hepatol* 2005; 20: 1712–20.
- 72 Banerjee A, Datta S, Chandra PK, Roychowdhury S, Panda CK, Chakravarty R. Distribution of hepatitis B virus genotypes: phylogenetic analysis and virological characteristics of genotype C circulating among HBV carriers in Kolkata, Eastern India. *World J Gastroenterol* 2006; 12: 5964–71.
- 73 Banerjee A, Kurbanov F, Datta S *et al.* Phylogenetic relatedness and genetic diversity of hepatitis B virus isolates in Eastern India. *J Med Virol* 2006; 78: 1164–74.
- 74 Murhekar MV, Chakravarty R, Murhekar KM, Banerjee A, Sehgal SC. Hepatitis B virus genotypes among the Jarawas: a primitive Negrito tribe of Andaman and Nicobar Islands, India. *Arch Virol* 2006; 151: 1499–510.
- 75 Datta S, Chandra PK, Banerjee A, Chakravarty R, Murhekar KM, Murhekar MV. Predominance of hepatitis B virus genotype C among Karens, the “old settlers” of Andaman and Nicobar Islands, India. *Arch Virol* 2007; 152: 1223–8.
- 76 Arankalle VA, Murhekar KM, Gandhe SS *et al.* Hepatitis B virus: predominance of genotype D in primitive tribes of the Andaman and Nicobar islands, India (1989–1999). *J Gen Virol* 2003; 84: 1915–20.
- 77 Alam MM, Zaidi SZ, Shaikat S *et al.* Common genotypes of Hepatitis B virus prevalent in injecting drug abusers (addicts) of North West Frontier Province of Pakistan. *Virol J* 2007; 4: 63.
- 78 Alam MM, Zaidi SZ, Malik SA *et al.* Molecular epidemiology of Hepatitis B virus genotypes in Pakistan. *BMC Infect Dis* 2007; 7: 115.
- 79 Abbas Z, Muzaffar R, Siddiqui A, Naqvi SA, Rizvi SA. Genetic variability in the precore and core promoter regions of hepatitis B virus strains in Karachi. *BMC Gastroenterol* 2006; 6: 20.
- 80 Olinger CM, Lazouskaya NV, Eremin VF, Muller CP. Multiple genotypes and subtypes of hepatitis B and C viruses in Belarus: similarities with Russia and western European influences. *Clin Microbiol Infect* 2008; 14: 575–81.
- 81 Deterding K, Constantinescu I, Nedelcu FD *et al.* Prevalence of HBV genotypes in Central and Eastern Europe. *J Med Virol* 2008; 80: 1707–11.
- 82 Krekulova L, Rehak V, da Silva Filho HP, Zavoral M, Riley LW. Genotypic distribution of hepatitis B virus in the Czech Republic: a possible association with modes of transmission and clinical outcome. *Eur J Gastroenterol Hepatol* 2003; 15: 1183–8.
- 83 Nemecek V, Strunecky O. [Hepatitis B virus (HBV) genotypes in the Czech Republic]. *Epidemiol Mikrobiol Imunol* 2004; 53: 55–61.
- 84 Tallo T, Norder H, Tefanova V *et al.* Hepatitis B virus genotype D strains from Estonia share sequence similarity with strains from Siberia and may specify ayw4. *J Med Virol* 2004; 74: 221–7.
- 85 Szomor KN, Dencs A, Toth G *et al.* Variability of the PreS1/PreS2/S regions of hepatitis B virus in Hungary. *Arch Virol* 2007; 152: 697–704.
- 86 Manuilov VA, Netesova IG, Osipova LP *et al.* [Genetic variability of hepatitis B virus isolates among population of Shuryksarsky area of Yamal-Nenets autonomous region]. *Mol Gen Mikrobiol Virusol* 2005; 4: 30–4.

- 87 Micalessi MI, De Cock L, Vranckx R. Hepatitis B virus (HBV) genotyping in Belgian patients with chronic HBV infection. *Clin Microbiol Infect* 2005; 11: 499–501.
- 88 Tran N, Berne R, Chann R *et al.* European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes. *J Clin Microbiol* 2006; 44: 2792–800.
- 89 Wintermeyer P, Gerner P, Gehring S, Karimi A, Wirth S. Prevalence of hepatitis B virus precore stop codon mutations in chronically infected children. *World J Gastroenterol* 2006; 12: 2235–8.
- 90 Oommen PT, Wirth S, Wintermeyer P, Gerner P. Relationship between viral load and genotypes of hepatitis B virus in children with chronic hepatitis B. *J Pediatr Gastroenterol Nutr* 2006; 43: 342–7.
- 91 Hannoun C, Krogsgaard K, Horal P, Lindh M. Genotype mixtures of hepatitis B virus in patients treated with interferon. *J Infect Dis* 2002; 186: 752–9.
- 92 Soussan P, Pol J, Garreau F *et al.* Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. *J Infect Dis* 2008; 198: 218–25.
- 93 Ganne-Carrie N, Williams V, Kaddouri H *et al.* Significance of hepatitis B virus genotypes A to E in a cohort of patients with chronic hepatitis B in the Seine Saint Denis District of Paris (France). *J Med Virol* 2006; 78: 335–40.
- 94 Trimoulet P, Boutonnet M, Winnock M *et al.* Hepatitis B virus genotypes: a retrospective survey in Southwestern France, 1999–2004. *Gastroenterol Clin Biol* 2007; 31: 1088–94.
- 95 Halfon P, Bourliere M, Pol S *et al.* Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status. *J Viral Hepat* 2006; 13: 329–35.
- 96 Pas SD, Tran N, de Man RA, Burghoorn-Maas C, Vernet G, Niesters HG. Comparison of reverse hybridization, microarray, and sequence analysis for genotyping hepatitis B virus. *J Clin Microbiol* 2008; 46: 1268–73.
- 97 Protzer-Knolle U, Naumann U, Bartenschlager R *et al.* Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. *Hepatology* 1998; 27: 254–63.
- 98 Zacharakis G, Koskinas J, Kotsiou S *et al.* Natural history of chronic hepatitis B virus infection in children of different ethnic origins: a cohort study with up to 12 years' follow-up in northern Greece. *J Pediatr Gastroenterol Nutr* 2007; 44: 84–91.
- 99 Lok AS, Hussain M, Cursano C *et al.* Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. *Hepatology* 2000; 32: 1145–53.
- 100 De Maddalena C, Giambelli C, Tanzi E *et al.* High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus. *Virology* 2007; 365: 113–24.
- 101 Dal Molin G, Poli A, Croce LS *et al.* Hepatitis B virus genotypes, core promoter variants, and precore stop codon variants in patients infected chronically in North-Eastern Italy. *J Med Virol* 2006; 78: 734–40.
- 102 Koppelman MH, Zaaier HL. Diversity and origin of hepatitis B virus in Dutch blood donors. *J Med Virol* 2004; 73: 29–32.
- 103 Toy M, Veldhuijzen IK, Mostert MC, de Man RA, Richardus JH. Transmission routes of hepatitis B virus infection in chronic hepatitis B patients in the Netherlands. *J Med Virol* 2008; 80: 399–404.
- 104 Bielawski KP, Charmuszko U, Dybikowska A, Stalke P, Podhajska AJ. Genetic variability of hepatitis B virus isolates in Poland. *Virus Genes* 2006; 33: 77–86.
- 105 Zalewska M, Domagala M, Simon K, Gladysz A. [Hepatitis B virus genotypes and the response to lamivudine therapy]. *Pol Arch Med Wewn* 2005; 114: 1190–9.
- 106 Dzierzanowska-Fangrat K, Woynarowski M, Szczypińska I *et al.* Hepatitis B virus genotypes in children with chronic hepatitis B in Poland. *Eur J Gastroenterol Hepatol* 2006; 18: 655–8.
- 107 Basaras M, Arrese E, Blanco S, Sota M, de las Heras B, Cisterna R. Characterization of hepatitis B virus genotypes in chronically infected patients. *Rev Esp Quimioter* 2007; 20: 442–5.
- 108 Ding X, Park YN, Taltavull TC *et al.* Geographic characterization of hepatitis virus infections, genotyping of hepatitis B virus, and p53 mutation in hepatocellular carcinoma analyzed by in situ detection of viral genomes from carcinoma tissues: comparison among six different countries. *Jpn J Infect Dis* 2003; 56: 12–18.
- 109 Ramos B, Nunez M, Martin-Carbonero L *et al.* Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. *J Acquir Immune Defic Syndr* 2007; 44: 557–61.
- 110 Pena-Lopez MJ, Suarez-Bordon P, Garcia-Bardeci D, Rodriguez-San Roman JL, Perez-Gonzalez MC, Lafarga-Capuz B. [Hepatitis B virus genotypes in chronic carriers on the island of Gran Canaria. Clinical and epidemiological characteristics]. *Enferm Infecc Microbiol Clin* 2005; 23: 415–18.
- 111 Jardi R, Rodriguez F, Buti M *et al.* Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers. *J Hepatol* 2004; 40: 507–14.
- 112 Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. *Gastroenterology* 2002; 123: 1848–56.
- 113 Avellon A, Echevarria JM. Frequency of hepatitis B virus "a" determinant variants in unselected Spanish chronic carriers. *J Med Virol* 2006; 78: 24–36.
- 114 Echevarria JM, Avellon A, Magnius LO. Molecular epidemiology of hepatitis B virus in Spain: identification of

- viral genotypes and prediction of antigenic subtypes by limited sequencing. *J Med Virol* 2005; 76: 176–84.
- 115 Echevarria JM, Leon P. Hepatitis B virus genotypes identified by a Line Probe Assay (LiPA) among chronic carriers from Spain. *Enferm Infecc Microbiol Clin* 2004; 22: 452–4.
  - 116 Rodriguez-Frias F, Jardi R, Buti M *et al.* Hepatitis B virus genotypes and G1896A precore mutation in 486 Spanish patients with acute and chronic HBV infection. *J Viral Hepat* 2006; 13: 343–50.
  - 117 Bjornsdottir TB, Stanzeit B, Sallberg M, Love A, Hultgren C. Changing prevalence of hepatitis B virus genotypes in Iceland. *J Med Virol* 2005; 77: 481–5.
  - 118 Laoi BN, Crowley B. Molecular characterization of hepatitis B virus (HBV) isolates, including identification of a novel recombinant, in patients with acute HBV infection attending an Irish hospital. *J Med Virol* 2008; 80: 1554–64.
  - 119 Blackberg J, Kidd-Ljunggren K. Genotypic differences in the hepatitis B virus core promoter and precore sequences during seroconversion from HBeAg to anti-HBe. *J Med Virol* 2000; 60: 107–12.
  - 120 Lindh M, Gonzalez JE, Norkrans G, Horal P. Genotyping of hepatitis B virus by restriction pattern analysis of a pre-S amplicon. *J Virol Methods* 1998; 72: 163–74.
  - 121 Dervisevic S, Ijaz S, Chaudry S, Tedder RS. Non-A hepatitis B virus genotypes in antenatal clinics, United Kingdom. *Emerg Infect Dis* 2007; 13: 1689–93.
  - 122 Davidson F, Lycett C, Sablon E, Petrik J, Dow BC. Hepatitis B virus genotypes and precore mutations in Scottish blood donors. *Vox Sang* 2005; 88: 87–92.
  - 123 Fung SK, Wong FS, Wong DK, Hussain MT, Lok AS. Hepatitis B virus genotypes, precore and core promoter variants among predominantly Asian patients with chronic HBV infection in a Canadian center. *Liver Int* 2006; 26: 796–804.
  - 124 Osiowy C, Giles E. Evaluation of the INNO-LiPA HBV genotyping assay for determination of hepatitis B virus genotype. *J Clin Microbiol* 2003; 41: 5473–7.
  - 125 Krarup HB, Andersen S, Madsen PH, Okkels H, Hvingel BH, Laurberg P. Benign course of long-standing hepatitis B virus infection among Greenland Inuit? *Scand J Gastroenterol* 2008; 43: 334–43.
  - 126 Sakurai M, Sugauchi F, Tsai N *et al.* Genotype and phylogenetic characterization of hepatitis B virus among multi-ethnic cohort in Hawaii. *World J Gastroenterol* 2004; 10: 2218–22.
  - 127 Germer JJ, Charlton MR, Ishitani MB, Forehand CD, Patel R. Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant. *Am J Transplant* 2003; 3: 743–53.
  - 128 Kato H, Gish RG, Bzowej N *et al.* Eight genotypes (A–H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics. *J Med Virol* 2004; 73: 516–21.
  - 129 Moriya T, Kuramoto IK, Yoshizawa H, Holland PV. Distribution of hepatitis B virus genotypes among American blood donors determined with a PreS2 epitope enzyme-linked immunosorbent assay kit. *J Clin Microbiol* 2002; 40: 877–80.
  - 130 Chu CJ, Keeffe EB, Han SH *et al.* Hepatitis B virus genotypes in the United States: results of a nationwide study. *Gastroenterology* 2003; 125: 444–51.
  - 131 Livingston SE, Simonetti JP, McMahon BJ *et al.* Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. *J Infect Dis* 2007; 195: 5–11.
  - 132 Sanchez LV, Maldonado M, Bastidas-Ramirez BE, Norder H, Panduro A. Genotypes and S-gene variability of Mexican hepatitis B virus strains. *J Med Virol* 2002; 68: 24–32.
  - 133 Sanchez LV, Tanaka Y, Maldonado M, Mizokami M, Panduro A. Difference of hepatitis B virus genotype distribution in two groups of Mexican patients with different risk factors. High prevalence of genotype H and G. *Intervirology* 2007; 50: 9–15.
  - 134 Alvarado-Esquivel C, Sablon E, Conde-Gonzalez CJ, Juarez-Figueroa L, Ruiz-Maya L, Aguilar-Benavides S. Molecular analysis of hepatitis B virus isolates in Mexico: predominant circulation of hepatitis B virus genotype H. *World J Gastroenterol* 2006; 12: 6540–5.
  - 135 Arauz-Ruiz P, Norder H, Visona KA, Magnus LO. Genotype F prevails in HBV infected patients of hispanic origin in Central America and may carry the precore stop mutant. *J Med Virol* 1997; 51: 305–12.
  - 136 Mbayed VA, Lopez JL, Telenta PF *et al.* Distribution of hepatitis B virus genotypes in two different pediatric populations from Argentina. *J Clin Microbiol* 1998; 36: 3362–5.
  - 137 Lopez JL, Mbayed VA, Telenta PF, Gonzalez JE, Campos RH. "Hbe minus" mutants of hepatitis B virus. Molecular characterization and its relation to viral genotypes. *Virus Res* 2002; 87: 41–9.
  - 138 Quarleri J, Moretti F, Bouzas MB *et al.* Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B. *AIDS Res Hum Retroviruses* 2007; 23: 525–31.
  - 139 Trinks J, Cuestas ML, Tanaka Y *et al.* Two simultaneous hepatitis B virus epidemics among injecting drug users and men who have sex with men in Buenos Aires, Argentina: characterization of the first D/A recombinant from the American continent. *J Viral Hepat* 2008; 15: 827–38.
  - 140 Franca PH, Gonzalez JE, Munne MS *et al.* Strong association between genotype F and hepatitis B virus (HBV) e antigen-negative variants among HBV-infected argentinian blood donors. *J Clin Microbiol* 2004; 42: 5015–21.
  - 141 Pineiro YLFG, Pezzano SC, Torres C *et al.* Hepatitis B virus genetic diversity in Argentina: Dissimilar genotype distri-

- buton in two different geographical regions; description of hepatitis B surface antigen variants. *J Clin Virol* 2008; 42: 381–8.
- 142 Khan A, Tanaka Y, Saito H *et al.* Transmission of hepatitis B virus (HBV) genotypes among Japanese immigrants and natives in Bolivia. *Virus Res* 2008; 132: 174–80.
- 143 Matos MA, Bringel RM, Franca DD *et al.* Epidemiology of hepatitis B virus infection in truck drivers in Brazil, South America. *Sex Transm Infect* 2008; 84: 386–9.
- 144 Ferreira RC, Teles SA, Dias MA *et al.* Hepatitis B virus infection profile in hemodialysis patients in Central Brazil: prevalence, risk factors, and genotypes. *Mem Inst Oswaldo Cruz* 2006; 101: 689–92.
- 145 Motta-Castro AR, Martins RM, Yoshida CF *et al.* Hepatitis B virus infection in isolated Afro-Brazilian communities. *J Med Virol* 2005; 77: 188–93.
- 146 Ribeiro NR, Campos GS, Angelo AL *et al.* Distribution of hepatitis B virus genotypes among patients with chronic infection. *Liver Int* 2006; 26: 636–42.
- 147 Sitnik R, Pinho JR, Bertolini DA, Bernardini AP, Da Silva LC, Carrilho FJ. Hepatitis B virus genotypes and precore and core mutants in Brazilian patients. *J Clin Microbiol* 2004; 42: 2455–60.
- 148 Araujo NM, Mello FC, Yoshida CF, Niel C, Gomes SA. High proportion of subgroup A' (genotype A) among Brazilian isolates of Hepatitis B virus. *Arch Virol* 2004; 149: 1383–95.
- 149 Mello FC, Souto FJ, Nabuco LC *et al.* Hepatitis B virus genotypes circulating in Brazil: molecular characterization of genotype F isolates. *BMC Microbiol* 2007; 7: 103.
- 150 Viana S, Parana R, Moreira RC, Compri AP, Macedo V. High prevalence of hepatitis B virus and hepatitis D virus in the western Brazilian Amazon. *Am J Trop Med Hyg* 2005; 73: 808–14.
- 151 de Oliveira CM, Farias IP, Ferraz da Fonseca JC, Brasil LM, de Souza R, Astolfi-Filho S. Phylogeny and molecular genetic parameters of different stages of hepatitis B virus infection in patients from the Brazilian Amazon. *Arch Virol* 2008; 153: 823–30.
- 152 Teles SA, Martins RM, Gomes SA *et al.* Hepatitis B virus transmission in Brazilian hemodialysis units: serological and molecular follow-up. *J Med Virol* 2002; 68: 41–9.
- 153 Blitz L, Pujol FH, Swenson PD *et al.* Antigenic diversity of hepatitis B virus strains of genotype F in Amerindians and other population groups from Venezuela. *J Clin Microbiol* 1998; 36: 648–51.
- 154 Devesa M, Rodriguez C, Leon G, Liprandi F, Pujol FH. Clade analysis and surface antigen polymorphism of hepatitis B virus American genotypes. *J Med Virol* 2004; 72: 377–84.
- 155 Devesa M, Loureiro CL, Rivas Y *et al.* Subgenotype diversity of hepatitis B virus American genotype F in Amerindians from Venezuela and the general population of Colombia. *J Med Virol* 2008; 80: 20–6.
- 156 Nakano T, Lu L, Hu X *et al.* Characterization of hepatitis B virus genotypes among Yucpa Indians in Venezuela. *J Gen Virol* 2001; 82: 359–65.
- 157 Quintero A, Martinez D, Alarcon De Noya B *et al.* Molecular epidemiology of hepatitis B virus in Afro-Venezuelan populations. *Arch Virol* 2002; 147: 1829–36.
- 158 Huy TT, Sall AA, Reynes JM, Abe K. Complete genomic sequence and phylogenetic relatedness of hepatitis B virus isolates in Cambodia. *Virus Genes* 2008; 36: 299–305.
- 159 Huy TT, Ushijima H, Quang VX *et al.* Characteristics of core promoter and precore stop codon mutants of hepatitis B virus in Vietnam. *J Med Virol* 2004; 74: 228–36.
- 160 Srey CT, Ijaz S, Tedder RS, Monchy D. Characterization of hepatitis B surface antigen strains circulating in the Kingdom of Cambodia. *J Viral Hepat* 2006; 13: 62–6.
- 161 Nurainy N, Muljono DH, Sudoyo H, Marzuki S. Genetic study of hepatitis B virus in Indonesia reveals a new subgenotype of genotype B in east Nusa Tenggara. *Arch Virol* 2008; 153: 1057–65.
- 162 Lusida MI, Surayah, Sakugawa H *et al.* Genotype and subtype analyses of hepatitis B virus (HBV) and possible co-infection of HBV and hepatitis C virus (HCV) or hepatitis D virus (HDV) in blood donors, patients with chronic liver disease and patients on hemodialysis in Surabaya, Indonesia. *Microbiol Immunol* 2003; 47: 969–75.
- 163 Lusida MI, Nugrahaputra VE, Soetjipto. Novel subgenotypes of hepatitis B virus genotypes C and D in Papua, Indonesia. *J Clin Microbiol* 2008; 46: 2160–6.
- 164 Ong HT, Duraisamy G, Kee Peng N, Wen Siang T, Seow HF. Genotyping of hepatitis B virus in Malaysia based on the nucleotide sequence of preS and S genes. *Microbes Infect* 2005; 7: 494–500.
- 165 Lim CK, Tan JT, Khoo JB *et al.* Correlations of HBV genotypes, mutations affecting HBeAg expression and HBeAg/anti-HBe status in HBV carriers. *Int J Med Sci* 2006; 3: 14–20.
- 166 Nagasaki F, Niitsuma H, Cervantes JG *et al.* Analysis of the entire nucleotide sequence of hepatitis B virus genotype B in the Philippines reveals a new subgenotype of genotype B. *J Gen Virol* 2006; 87: 1175–80.
- 167 Sakamoto T, Tanaka Y, Orito E *et al.* Novel subtypes (subgenotypes) of hepatitis B virus genotypes B and C among chronic liver disease patients in the Philippines. *J Gen Virol* 2006; 87: 1873–82.
- 168 Tangkijvanich P, Mahachai V, Komolmit P, Fongsarun J, Theamboonlers A, Poovorawan Y. Hepatitis B virus genotypes and hepatocellular carcinoma in Thailand. *World J Gastroenterol* 2005; 11: 2238–43.
- 169 Jutavijittum P, Yousukh A, Jiviriyawat Y, Kunachiwa W, Toriyama K. Genotypes of hepatitis B virus among children in Chiang Mai, Thailand. *Southeast Asian J Trop Med Public Health* 2008; 39: 394–7.
- 170 Thuy le TT, Ryo H, Van Phung L, Furitsu K, Nomura T. Distribution of genotype/subtype and mutational spectra

- of the surface gene of hepatitis B virus circulating in Hanoi, Vietnam. *J Med Virol* 2005; 76: 161–9.
- 171 Lin X, Ma ZM, Yao X, Zhang YP, Wen YM. Replication efficiency and sequence analysis of full-length hepatitis B virus isolates from hepatocellular carcinoma tissues. *Int J Cancer* 2002; 102: 487–91.
- 172 Guo PF, Zhong M, Hou JL. [Genotyping study of hepatitis B virus in its intrauterine transmission]. *Di Yi Jun Yi Da Xue Xue Bao* 2002; 22: 303–5.
- 173 Xu HM, Ren H, Qing YL, Peng ML, Ling N. [Establishment of consensus sequence of PreS/S of hepatitis B virus with genotype B/serotype adw2 or genotype C/serotype adrqt-prevaling in Chongqing of China]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2003; 24: 913–16.
- 174 Bian ZQ, Hua ZL, Yan WY, Liu MQ, Wu DY, Zheng ZX. [Identification of hepatitis B virus genotypes in patients with chronic hepatitis B from different nationalities in ethnic minority areas in Yunnan Province, China]. *Zhonghua Yi Xue Za Zhi* 2006; 86: 681–6.
- 175 Fan HB, Guo YB, Yang J *et al.* [Genotyping of hepatitis B virus and its clinical significance in patients with chronic hepatitis B]. *Di Yi Jun Yi Da Xue Xue Bao* 2005; 25: 229–30.
- 176 Song Y, Dai E, Wang J *et al.* Genotyping of hepatitis B virus (HBV) by oligonucleotides microarray. *Mol Cell Probes* 2006; 20: 121–7.
- 177 Zhu L, Tse CH, Wong VW, Chim AM, Leung KS, Chan HL. A complete genomic analysis of hepatitis B virus genotypes and mutations in HBeAg-negative chronic hepatitis B in China. *J Viral Hepat* 2008; 15: 449–58.
- 178 Kong HB, Li YS. [Distribution of hepatitis B virus genotypes and its clinical significance]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi* 2007; 21: 372–3.
- 179 Du H, Li T, Zhang HY *et al.* Correlation of hepatitis B virus (HBV) genotypes and mutations in basal core promoter/precore with clinical features of chronic HBV infection. *Liver Int* 2007; 27: 240–6.
- 180 You J, Sriplung H, Chongsuvivatwong V *et al.* Profile, spectrum and significance of hepatitis B virus genotypes in chronic HBV-infected patients in Yunnan, China. *Hepatobiliary Pancreat Dis Int* 2008; 7: 271–9.
- 181 Lu XB, Wang XL, Deng GH *et al.* [Distribution and characteristics of hepatitis B virus genotypes in Uighur patients with chronic hepatitis B in Xinjiang province of China]. *Zhonghua Gan Zang Bing Za Zhi* 2007; 15: 241–4.
- 182 Li D, Gu HX, Zhang SY, Zhong ZH, Zhuang M, Hattori T. YMDD mutations and genotypes of hepatitis B virus in northern China. *Jpn J Infect Dis* 2006; 59: 42–5.
- 183 Ding X, Mizokami M, Ge X *et al.* Different hepatitis B virus genotype distributions among asymptomatic carriers and patients with liver diseases in Nanning, southern China. *Hepatol Res* 2002; 22: 37–44.
- 184 Ding JJ, Peng L, Zhang Q, Li Z, Tang GP. [Distribution of hepatitis B virus genotype among population of Dong, Miao minority and Han in Guizhou]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi* 2004; 18: 230–3.
- 185 Ding JJ, Zhang Q, Peng L *et al.* [Distribution of hepatitis B virus genotypes in Guizhou and analysis of clinical significance]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi* 2006; 20: 241–3.
- 186 Ding J, Zhang Q, Peng L *et al.* [Investigation on virus genotype in patients infected with hepatitis B virus in four cities of Guizhou]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2006; 27: 977–80.
- 187 Ding X, Mizokami M, Yao G *et al.* Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China. *Intervirology* 2001; 44: 43–7.
- 188 Lei YC, Hao YH, Tian YJ *et al.* [Distribution of hepatitis B virus genotypes in Hubei province and its clinical significance]. *Zhonghua Gan Zang Bing Za Zhi* 2005; 13: 109–12.
- 189 Rokuhara A, Sun X, Tanaka E *et al.* Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection. *J Gastroenterol Hepatol* 2005; 20: 1726–30.
- 190 Wang Z, Tanaka Y, Huang Y *et al.* Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. *J Clin Microbiol* 2007; 45: 1491–6.
- 191 Wang Y, Zhou G, Li X *et al.* [Genotyping of hepatitis B virus and clinical investigation]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi* 2002; 16: 367–9.
- 192 Ge XM, Li DY, Fang ZL *et al.* [Distribution of hepatitis B virus genotypes and its clinical significance in Guangxi]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi* 2003; 17: 174–9.
- 193 Cui C, Shi J, Hui L *et al.* The dominant hepatitis B virus genotype identified in Tibet is a C/D hybrid. *J Gen Virol* 2002; 83: 2773–7.
- 194 Yuen MF, Sablon E, Tanaka Y *et al.* Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. *J Hepatol* 2004; 41: 119–25.
- 195 Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. *Gastroenterology* 2002; 122: 1756–62.
- 196 Chan HL, Tsang SW, Liew CT *et al.* Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. *Am J Gastroenterol* 2002; 97: 406–12.
- 197 Chan HL, Wong ML, Hui AY, Hung LC, Chan FK, Sung JJ. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. *J Clin Microbiol* 2003; 41: 1277–9.
- 198 Chan HL, Tsang SW, Wong ML *et al.* Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. *Am J Gastroenterol* 2002; 97: 2629–33.

- 199 Chan HL, Wong ML, Hui AY *et al.* Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. *World J Gastroenterol* 2003; 9: 2695–7.
- 200 Yuan J, Zhou B, Tanaka Y *et al.* Hepatitis B virus (HBV) genotypes/subgenotypes in China: mutations in core promoter and precore/core and their clinical implications. *J Clin Virol* 2007; 39: 87–93.
- 201 Huang YH, Zhou B, Wang ZH, Ma SW, Liang MF, Hou JL. [Distribution of hepatitis B virus genotype B subgenotype in China]. *Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi* 2007; 21: 111–13.
- 202 Li YJ, Zhuang H, Li J *et al.* [Distribution and clinical significance of hepatitis B virus (HBV) genotypes and subtypes in HBV-infected patients]. *Zhonghua Gan Zang Bing Za Zhi* 2005; 13: 724–9.
- 203 Yuen MF, Tanaka Y, Shinkai N *et al.* Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. *Gut* 2008; 57: 98–102.
- 204 Zhao H, Li J, Li XF *et al.* [Clinical characteristics and distribution of hepatitis B virus genotype and sub-genotype]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2007; 28: 74–7.
- 205 Zeng G, Wang Z, Wen S *et al.* Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. *J Viral Hepat* 2005; 12: 609–17.
- 206 Yin J, Zhang H, Li C *et al.* Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area. *Carcinogenesis* 2008; 28: 1685–91.
- 207 Liu YX, Hu GL, Tan DM. [Distribution of hepatitis B virus genotype in Hunan Province and its clinical significance]. *Hunan Yi Ke Da Xue Xue Bao* 2002; 27: 29–31.
- 208 Xia G, Nainan OV, Jia Z. [Characterization and distribution of hepatitis B virus genotypes and subtypes in 4 provinces of China]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2001; 22: 348–51.
- 209 Takahashi K, Ohta Y, Kanai K *et al.* Clinical implications of mutations C-to-T1653 and T-to-C/A/G1753 of hepatitis B virus genotype C genome in chronic liver disease. *Arch Virol* 1999; 144: 1299–308.
- 210 Sumi H, Yokosuka O, Seki N *et al.* Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. *Hepatology* 2003; 37: 19–26.
- 211 Moriyama M, Taira M, Matsumura H *et al.* Genotype analysis, using PCR with type-specific primers, of hepatitis B virus isolates from patients coinfecting with hepatitis delta virus genotype II from Miyako Island, Japan. *Inter-virology* 2003; 46: 114–20.
- 212 Lin ZM, Yatsushashi H, Daikoku M *et al.* Hepatitis B virus of genotype C persistence after recovery from acute hepatitis B virus infection in Japan. *Hepatol Res* 2003; 25: 244–53.
- 213 Ogawa M, Hasegawa K, Naritomi T, Torii N, Hayashi N. Clinical features and viral sequences of various genotypes of hepatitis B virus compared among patients with acute hepatitis B. *Hepatol Res* 2002; 23: 167–77.
- 214 Tsubota A, Arase Y, Ren F, Tanaka H, Ikeda K, Kumada H. Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw. *J Med Virol* 2001; 65: 257–65.
- 215 Joh R, Hasegawa K, Ogawa M *et al.* Genotypic analysis of hepatitis B virus from patients with fulminant hepatitis: comparison with acute self-limited hepatitis. *Hepatol Res* 2003; 26: 119–24.
- 216 Shibayama T, Masuda G, Ajisawa A *et al.* Characterization of seven genotypes (A to E, G and H) of hepatitis B virus recovered from Japanese patients infected with human immunodeficiency virus type 1. *J Med Virol* 2005; 76: 24–32.
- 217 Seo Y, Yoon S, Truong BX *et al.* Serum hepatitis B virus DNA levels differentiating inactive carriers from patients with chronic hepatitis B. *Eur J Gastroenterol Hepatol* 2005; 17: 753–7.
- 218 Aono J, Yotsuyanagi H, Miyoshi H *et al.* Amino acid substitutions in the S region of hepatitis B virus in sera from patients with acute hepatitis. *Hepatol Res* 2007; 37: 731–9.
- 219 Kobayashi M, Arase Y, Ikeda K *et al.* Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. *J Med Virol* 2002; 68: 522–8.
- 220 Kobayashi M, Arase Y, Ikeda K *et al.* Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C. *J Gastroenterol* 2002; 37: 35–9.
- 221 Inui A, Komatsu H, Sogo T, Nagai T, Abe K, Fujisawa T. Hepatitis B virus genotypes in children and adolescents in Japan: before and after immunization for the prevention of mother to infant transmission of hepatitis B virus. *J Med Virol* 2007; 79: 670–5.
- 222 Hayashi K, Katano Y, Takeda Y *et al.* Association of hepatitis B virus subgenotypes and basal core promoter/precore region variants with the clinical features of patients with acute hepatitis. *J Gastroenterol* 2008; 43: 558–64.
- 223 Yotsuyanagi H, Okuse C, Yasuda K *et al.* Distinct geographic distributions of hepatitis B virus genotypes in patients with acute infection in Japan. *J Med Virol* 2005; 77: 39–46.
- 224 Furusyo N, Nakashima H, Kashiwagi K *et al.* Clinical outcomes of hepatitis B virus (HBV) genotypes B and C in Japanese patients with chronic HBV infection. *Am J Trop Med Hyg* 2002; 67: 151–7.
- 225 Furusyo N, Kubo N, Nakashima H, Kashiwagi K, Hayashi J. Relationship of genotype rather than race to hepatitis B virus pathogenicity: a study of Japanese and Solomon Islanders. *Am J Trop Med Hyg* 2004; 70: 571–5.

- 226 Hayashi K, Katano Y, Takeda Y *et al.* Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan. *J Med Virol* 2007; 79: 366–73.
- 227 Ozasa A, Tanaka Y, Orito E *et al.* Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. *Hepatology* 2006; 44: 326–34.
- 228 Sakugawa H, Nakasone H, Nakayoshi T *et al.* Preponderance of hepatitis B virus genotype B contributes to a better prognosis of chronic HBV infection in Okinawa, Japan. *J Med Virol* 2002; 67: 484–9.
- 229 Sugauchi F, Orito E, Ohno T *et al.* Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. *Hepatol Res* 2006; 36: 107–14.
- 230 Suzuki F, Tsubota A, Arase Y *et al.* Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. *Intervirology* 2003; 46: 182–9.
- 231 Usuda S, Okamoto H, Iwanari H *et al.* Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. *J Virol Methods* 1999; 80: 97–112.
- 232 Orito E, Ichida T, Sakugawa H *et al.* Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. *Hepatology* 2001; 34: 590–4.
- 233 Odgerel Z, Nho KB, Moon JY *et al.* Complete genome sequence and phylogenetic analysis of hepatitis B virus (HBV) isolates from patients with chronic HBV infection in Korea. *J Med Virol* 2003; 71: 499–503.
- 234 Odgerel Z, Choi IK, Byun KS *et al.* Complete genome sequence and phylogenetic analysis of hepatitis B virus (HBV) isolated from Mongolian patients with chronic HBV infection. *Virus Genes* 2006; 33: 345–9.
- 235 Bae SH, Yoon SK, Jang JW *et al.* Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. *J Korean Med Sci* 2005; 20: 816–20.
- 236 Song BC, Cui XJ, Kim H. Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection. *Intervirology* 2005; 48: 133–7.
- 237 Kim H, Jee YM, Song BC *et al.* Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea. *Intervirology* 2007; 50: 52–7.
- 238 Yoon YJ, Chang HY, Ahn SH *et al.* MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. *Carcinogenesis* 2008; 29: 1192–6.
- 239 Alestig E, Hannoun C, Horal P, Lindh M. Hepatitis B virus genotypes in Mongols and Australian Aborigines. *Arch Virol* 2001; 146: 2321–9.
- 240 Oyunsuren T, Kurbanov F, Tanaka Y *et al.* High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses. *J Med Virol* 2006; 78: 1688–95.
- 241 Davaalkham D, Ojima T, Uehara R *et al.* Analysis of hepatitis B surface antigen mutations in Mongolia: molecular epidemiology and implications for mass vaccination. *Arch Virol* 2007; 152: 575–84.
- 242 Tsatsralt-Od B, Takahashi M, Nishizawa T, Endo K, Inoue J, Okamoto H. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. *J Med Virol* 2005; 77: 491–9.
- 243 Tsai WL, Lo GH, Hsu PI *et al.* Role of genotype and precore/basal core promoter mutations of hepatitis B virus in patients with chronic hepatitis B with acute exacerbation. *Scand J Gastroenterol* 2008; 43: 196–201.
- 244 Kao JH, Chen PJ, Lai MY, Chen DS. Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus. *Hepatology* 2001; 34: 817–23.
- 245 Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. *J Med Virol* 2004; 72: 363–9.
- 246 Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis D virus genotypes in intravenous drug users in Taiwan: decreasing prevalence and lack of correlation with hepatitis B virus genotypes. *J Clin Microbiol* 2002; 40: 3047–9.
- 247 Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. *Gastroenterology* 2003; 124: 327–34.
- 248 Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. *J Clin Microbiol* 2002; 40: 1207–9.
- 249 Kao JH, Chen PJ, Lai MY, Chen DS. Clinical and virological aspects of blood donors infected with hepatitis B virus genotypes B and C. *J Clin Microbiol* 2002; 40: 22–5.
- 250 Lee CM, Chen CH, Lu SN *et al.* Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. *Scand J Gastroenterol* 2003; 38: 95–101.
- 251 Lin CL, Liu CJ, Chen PJ, Lai MY, Chen DS, Kao JH. High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users. *J Med Virol* 2007; 79: 1674–8.
- 252 Chen CH, Lee CM, Lu SN *et al.* Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. *J Clin Microbiol* 2005; 43: 6000–6.
- 253 Chen BF, Chen PJ, Jow GM *et al.* High prevalence of mixed genotype infections in hepatitis B virus infected intravenous drug users. *J Med Virol* 2004; 74: 536–42.



- 254 Ni YH, Chang MH, Wang KJ *et al.* Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. *Gastroenterology* 2004; 127: 1733–8.
- 255 Yang C, Liu J, Han S *et al.* Association between hepatitis B virus infection and HLA-DRB1 genotyping in Shaanxi Han patients in northwestern China. *Tissue Antigens* 2007; 69: 170–5.
- 256 Sugauchi F, Mizokami M, Orito E *et al.* A novel variant genotype C of hepatitis B virus identified in isolates from Australian Aborigines: complete genome sequence and phylogenetic relatedness. *J Gen Virol* 2001; 82: 883–92.
- 257 Jazayeri MS, Basuni AA, Cooksley G, Locarnini S, Carman WF. Hepatitis B virus genotypes, core gene variability and ethnicity in the Pacific region. *J Hepatol* 2004; 41: 139–46.
- 258 Kessler HH, Stelzl E, Marth E, Stauber RE. Detection of mutations in the hepatitis B virus polymerase gene. *Clin Chem* 2003; 49: 989–92.
- 259 Cooley L, Ayres A, Bartholomew A *et al.* Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. *AIDS* 2003; 17: 1649–57.
- 260 Bell SJ, Lau A, Thompson A *et al.* Chronic hepatitis B: recommendations for therapy based on the natural history of disease in Australian patients. *J Clin Virol* 2005; 32: 122–7.
- 261 Sugauchi F, Kumada H, Acharya SA *et al.* Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A. *J Gen Virol* 2004; 85: 811–20.
- 262 Kramvis A, Arakawa K, Yu MC, Nogueira R, Stram DO, Kew MC. Relationship of serological subtype, basic core promoter and precore mutations to genotypes/subgenotypes of hepatitis B virus. *J Med Virol* 2008; 80: 27–46.
- 263 Hannoun C, Soderstrom A, Norkrans G, Lindh M. Phylogeny of African complete genomes reveals a West African genotype A subtype of hepatitis B virus and relatedness between Somali and Asian A1 sequences. *J Gen Virol* 2005; 86: 2163–7.
- 264 Sugauchi F, Kumada H, Sakugawa H *et al.* Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan. *Clin Infect Dis* 2004; 38: 1222–8.
- 265 Sugauchi F, Orito E, Ichida T *et al.* Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. *Gastroenterology* 2003; 124: 925–32.
- 266 Sugauchi F, Orito E, Ichida T *et al.* Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. *J Virol* 2002; 76: 5985–92.
- 267 Wang Z, Huang Y, Wen S, Zhou B, Hou J. Hepatitis B virus genotypes and subgenotypes in China. *Hepatol Res* 2007; 37: S36–41.
- 268 Yuen MF, Tanaka Y, Mizokami M *et al.* Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. *Carcinogenesis* 2004; 25: 1593–8.
- 269 Norder H, Courouce AM, Coursaget P *et al.* Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. *Intervirology* 2004; 47: 289–309.
- 270 Sakamoto T, Tanaka Y, Simonetti J *et al.* Classification of hepatitis B virus genotype B into 2 major types based on characterization of a novel subgenotype in Arctic indigenous populations. *J Infect Dis* 2007; 196: 1487–92.
- 271 Osiowy C, Giles E, Tanaka Y, Mizokami M, Minuk GY. Molecular evolution of hepatitis B virus over 25 years. *J Virol* 2006; 80: 10307–14.
- 272 Chan HL, Tsui SK, Tse CH *et al.* Epidemiological and virological characteristics of 2 subgroups of hepatitis B virus genotype C. *J Infect Dis* 2005; 191: 2022–32.
- 273 Huy TT, Ushijima H, Quang VX *et al.* Genotype C of hepatitis B virus can be classified into at least two subgroups. *J Gen Virol* 2004; 85: 283–92.
- 274 Tanaka Y, Orito E, Yuen MF *et al.* Two subtypes (subgenotypes) of hepatitis B virus genotype C: a novel subtyping assay based on restriction fragment length polymorphism. *Hepatol Res* 2005; 33: 216–24.
- 275 Elkady A, Tanaka Y, Kurbanov F, Oyunsuren T, Mizokami M. Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia. *J Gastroenterol Hepatol* 2008; 23: 474–81.
- 276 Tallo T, Tefanova V, Priimagi L *et al.* D2: major subgenotype of hepatitis B virus in Russia and the Baltic region. *J Gen Virol* 2008; 89: 1829–39.
- 277 Michitaka K, Tanaka Y, Horiike N *et al.* Tracing the history of hepatitis B virus genotype D in western Japan. *J Med Virol* 2006; 78: 44–52.
- 278 Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. *Virology* 1994; 198: 489–503.
- 279 Kato H, Fujiwara K, Gish RG *et al.* Classifying genotype F of hepatitis B virus into F1 and F2 subtypes. *World J Gastroenterol* 2005; 11: 6295–304.
- 280 Norder H, Arauz-Ruiz P, Blitz L, Pujol FH, Echevarria JM, Magnius LO. The T(1858) variant predisposing to the precore stop mutation correlates with one of two major genotype F hepatitis B virus clades. *J Gen Virol* 2003; 84: 2083–7.
- 281 von Meltzer M, Vasquez S, Sun J *et al.* A new clade of hepatitis B virus subgenotype F1 from Peru with unusual properties. *Virus Genes* 2008; 37: 225–30.
- 282 Pineiro y Leone FG, Mbayed VA, Campos RH. Evolutionary history of Hepatitis B virus genotype F: an in-depth analysis of Argentine isolates. *Virus Genes* 2003; 27: 103–10.
- 283 Suwannakarn K, Tangkijvanich P, Theamboonlers A, Abe K, Poovorawan Y. A novel recombinant of Hepatitis B

- virus genotypes G and C isolated from a Thai patient with hepatocellular carcinoma. *J Gen Virol* 2005; 86: 3027–30.
- 284 Bottecchia M, Souto FJ, O KM *et al.* Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil. *BMC Microbiol* 2008; 8: 11.
- 285 Mizokami M, Orito E, Ohba K, Ikeo K, Lau JY, Gojobori T. Constrained evolution with respect to gene overlap of hepatitis B virus. *J Mol Evol* 1997; 44 (Suppl 1): S83–90.
- 286 Bollyky PL, Holmes EC. Reconstructing the complex evolutionary history of hepatitis B virus. *J Mol Evol* 1999; 49: 130–41.
- 287 Bollyky PL, Rambaut A, Harvey PH, Holmes EC. Recombination between sequences of hepatitis B virus from different genotypes. *J Mol Evol* 1996; 42: 97–102.
- 288 Simmonds P, Midgley S. Recombination in the genesis and evolution of hepatitis B virus genotypes. *J Virol* 2005; 79: 15467–76.
- 289 Yang J, Xing K, Deng R, Wang J, Wang X. Identification of Hepatitis B virus putative intergenotype recombinants by using fragment typing. *J Gen Virol* 2006; 87: 2203–15.
- 290 Arauz-Ruiz P, Norder H, Visona KA, Magnius LO. Molecular epidemiology of hepatitis B virus in Central America reflected in the genetic variability of the small S gene. *J Infect Dis* 1997; 176: 851–8.
- 291 Jutavijittum P, Jiviriyawat Y, Yousukh A, Kunachiwa W, Toriyama K. Genotypes of hepatitis B virus among voluntary blood donors in northern Thailand. *Hepato Res* 2006; 35: 263–6.
- 292 Kuiken C, Mizokami M, Deleage G *et al.* Hepatitis C databases, principles and utility to researchers. *Hepatology* 2006; 43: 1157–65.
- 293 Shin IT, Tanaka Y, Tateno Y, Mizokami M. Development and public release of a comprehensive hepatitis virus database. *Hepato Res* 2008; 38: 234–43.
- 294 Huy TT, Tran TT, Trinh TN, Abe K. New complex recombinant genotype of hepatitis B virus identified in Vietnam. *J Virol* 2008; 82: 5657–63.
- 295 Kurbanov F, Tanaka Y, Kramvis A, Simmonds P, Mizokami M. When should “I” consider a new hepatitis B virus genotype? *J Virol* 2008; 82: 8241–2.
- 296 Hannoun C, Norder H, Lindh M. An aberrant genotype revealed in recombinant hepatitis B virus strains from Vietnam. *J Gen Virol* 2000; 81: 2267–72.
- 297 Olinger CM, Jutavijittum P, Hubschen JM *et al.* Possible new hepatitis B virus genotype, southeast Asia. *Emerg Infect Dis* 2008; 14: 1777–80.
- 298 Tatematsu K, Tanaka Y, Kurbanov F *et al.* A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype I. *J Virol* 2009; 83: 10538–47.
- 299 Szmaraagd C, Balloux F. The population genomics of hepatitis B virus. *Mol Ecol* 2007; 16: 4747–58.
- 300 Purdy MA, Gonzales AC, Dimitrova Z, Khudyakov Y. Supragenotypic groups of the hepatitis B virus genome. *J Gen Virol* 2008; 89: 1179–83.

*Immunopathology and Infectious Diseases*

# Tacrolimus Ameliorates Metabolic Disturbance and Oxidative Stress Caused by Hepatitis C Virus Core Protein

## *Analysis Using Mouse Model and Cultured Cells*

Kyoji Moriya,\* Hideyuki Miyoshi,\*  
Takeya Tsutsumi,\* Seiko Shinzawa,\*  
Hajime Fujie,\* Yoshizumi Shintani,\*  
Hiroshi Yotsuyanagi,\* Kohji Moriishi,†  
Yoshiharu Matsuura,† Tetsuro Suzuki,‡  
Tatsuo Miyamura,‡ and Kazuhiko Koike\*

*From the Department of Internal Medicine,\* Graduate School of Medicine, University of Tokyo, Tokyo; the Department of Molecular Virology,† Research Institute for Microbial Diseases, Osaka University, Osaka; and the Department of Virology II,‡ National Institute of Infectious Diseases, Tokyo, Japan*

**Hepatic steatosis and insulin resistance are factors that aggravate the progression of liver disease caused by hepatitis C virus (HCV) infection. In the pathogenesis of liver disease and metabolic disorders in HCV infection, oxidative stress due to mitochondrial respiratory chain dysfunction plays a pivotal role. Tacrolimus (FK506) is supposed to protect mitochondrial respiratory function. We studied whether tacrolimus affects the development of HCV-associated liver disease using HCV core gene transgenic mice, which develop hepatic steatosis, insulin resistance, and hepatocellular carcinoma. Administration of tacrolimus to HCV core gene transgenic mice three times per week for 3 months led to a significant reduction in the amounts of lipid in the liver as well as in serum insulin. Tacrolimus treatment also ameliorated oxidative stress and DNA damage in the liver of the core gene transgenic mice. Tacrolimus administration reproduced these effects in a dose-dependent manner in HepG2 cells expressing the core protein. The intrahepatic level of tumor necrosis factor- $\alpha$ , which may be a key molecule for the pathogenesis in HCV infection, was significantly decreased in tacrolimus-treated core gene transgenic mice. Tacrolimus thus reversed the effect of the core protein in the patho-**

**genesis of HCV-associated liver disease. These results may provide new therapeutic tools for chronic hepatitis C, in which oxidative stress and abnormalities in lipid and glucose metabolism contribute to liver pathogenesis. (Am J Pathol 2009, 175:1515-1524; DOI: 10.2353/ajpath.2009.090102)**

Hepatitis C virus (HCV) is a major cause of liver disease; approximately 170 million people are chronically infected worldwide. Persistent HCV infection leads to the development of chronic hepatitis, cirrhosis, and, eventually, hepatocellular carcinoma (HCC), thereby being a serious problem from both medical and socioeconomic viewpoints.<sup>1,2</sup> Recently, a growing amount of evidence showing that HCV infection induces alteration in lipid<sup>3-7</sup> and glucose metabolism has accumulated.<sup>8,9</sup> Augmentation of oxidative stress is also substantiated in HCV infection by a number of clinical and basic studies.<sup>10-13</sup>

We demonstrated previously that the core protein of HCV induces HCC in transgenic mice that have marked hepatic steatosis in the absence of inflammation.<sup>14</sup> In this animal model for HCV-associated HCC, there is augmentation of oxidative stress in the liver during the incubation period.<sup>10</sup> Also noted is an accumulation of lipid droplets that are rich with carbon 18 monounsaturated fatty acids such as oleic and vaccenic acids, which is also observed in liver tissues of patients with chronic hepatitis C com-

Supported in part by a Grant-in-Aid for Scientific Research on Priority Area from the Ministry of Education, Science, Sports and Culture of Japan, by Health Sciences research grants from the Ministry of Health, Labour and Welfare (Research on Hepatitis), and by the Program for Promotion of Fundamental Studies in Health Sciences of the Organization for Drug ADR Relief, R&D Promotion and Product Review of Japan.

Accepted for publication June 22, 2009.

Address reprint requests to Kazuhiko Koike, M.D., Ph.D., Department of Gastroenterology, Internal Medicine, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail: kkoike-ky@umin.ac.jp.

pared with those in patients with fatty liver due to simple obesity.<sup>15</sup> Recently, we have also shown, using the HCV transgenic mouse model, that the ability of insulin to lower plasma glucose levels is impaired in association with HCV infection,<sup>16</sup> which would be the basis for the frequent development of type 2 diabetes in patients with chronic hepatitis C.<sup>8,9</sup>

Disturbances in lipid and glucose metabolism are notable features of HCV infection and may be profoundly involved in the pathogenesis of liver diseases. Although the mechanism underlying these phenomena is not yet well understood, the development of clues to correct these metabolic disturbances occurring in HCV infection, which have been recently connected to the poor prognosis of patients with chronic hepatitis C, is awaited. Moreover, a key role for oxidative stress in the pathogenesis of hepatitis C,<sup>11,12</sup> which may be closely associated with the aforementioned metabolic disorders, has been identified. The association of oxidative stress augmentation in HCV infection with mitochondrial respiratory dysfunction<sup>10,13,17</sup> suggests that one possibility to ameliorate such a condition is the use of agents that can protect the mitochondrial respiratory function.

We have conducted information retrieval and screening for agents that can protect the mitochondrial respiratory function. Tacrolimus (FK506), which is widely used in organ transplantation, is one such agent with evidence showing protection of the mitochondrial respiratory function,<sup>18-21</sup> although it shows no antiviral effect. We explored, using transgenic mouse and cultured cell models that express the HCV core protein, whether tacrolimus improves metabolic disturbances including lipid and glucose homeostases as well as oxidative stress augmentation through a possible involvement of mitochondrial function.

## Materials and Methods

### Transgenic Mouse and Cultured Cells

The production of *HCV core gene* transgenic mice has been described previously.<sup>6</sup> Mice were cared for according to institutional guidelines with the approval by the institutional review board of the animal care committee, fed an ordinary chow diet (Oriental Yeast Co., Ltd., Tokyo, Japan), and maintained in a specific pathogen-free state. Because there is a sex preference in the development of liver lesions in the transgenic mice, we used only male mice. At least five mice were used in each experiment, and the data were subjected to statistical analysis. HepG2 cell lines expressing the HCV core protein under the control of the CAG promoter (Hep39J, Hep396, and Hep397) or a control HepG2 line (Hepswx) carrying the empty vector were described previously.<sup>22,23</sup> Bulk HepG2 cells were also used as a control.

### Reagents

Cholesterol esters and lipid standards were purchased from Sigma-Aldrich (St. Louis, MO), and glycogen and

amyloglucosidase were obtained from Seikagaku Kogyo (Tokyo, Japan). Other chemicals were of analytical grade and were purchased from Wako Chemicals (Tokyo, Japan). Tacrolimus (FK506) was kindly provided by Astellas Pharma Inc. (Tokyo, Japan). Cyclosporine A (CyA) was purchased from Sigma-Aldrich.

### Administration of Tacrolimus and Cyclosporine A

Tacrolimus (0.1 mg/kg b.wt., suspended in mannitol and hydroxychlorinated castor oil [HCO-60]), or vehicle only was administered to the core gene transgenic or control mice i.p., three times per week for 3 months beginning at 3 months of age. For *in vitro* experiments, tacrolimus was added to the culture medium at the final concentration of 0 nmol/L, 10 nmol/L, 100 nmol/L, or 1  $\mu$ mol/L. CyA was also added to the culture medium at the same concentrations.

### Assessment of Glucose Homeostasis

Blood was drawn at different time points from the tail vein, and plasma glucose concentrations were measured using an automatic biochemical analyzer (DRI-CHEM 3000V, Fuji Film, Tokyo, Japan). The levels of serum insulin were determined by radioimmunoassay (Biotrak, Amersham Pharmacia Biotech, Piscataway, NJ) using rat insulin as a standard. For the determination of the fasting plasma glucose level, the mice were fasted for >16 hours before the study. An insulin tolerance test was performed as described previously.<sup>16</sup>

### Lipid Extraction, Measurement of Triglyceride Content, and Analysis of Fatty Acid Compositions

Lipid extraction from the mouse liver tissues or cultured cells was performed as described previously.<sup>15,24</sup> For the analysis of fatty acid compositions, the residue was methanolysed by the modified Morrison and Smith method with boron trifluoride as a catalyst.<sup>25</sup> Fatty acid methyl esters were analyzed using a Shimadzu GC-7A gas chromatograph (Shimadzu Corp., Kyoto, Japan) equipped with a 30-m-long  $\times$  0.3-mm diameter support coated with ethylene glycol succinate.<sup>24</sup>

### Evaluation of Oxidative and Antioxidative System

Lipid peroxidation was estimated spectrophotometrically using thiobarbituric acid-reactive substances and is expressed in terms of malondialdehyde formed per milligram protein. Reduced glutathione and oxidized glutathione levels were measured as described previously.<sup>10</sup> The total amount of glutathione was calculated by adding the amounts obtained for glutathione and oxidized glutathione. For the evaluation of DNA damage in cells, apurinic/aprimidinic sites were determined using a DNA Damage Quantification Kit (Dojindo Molecular Technolo-

gies, Inc., Tokyo, Japan) following the manufacturer's protocol.

### Determination of Reactive Oxygen Species

Cells were plated onto glass coverslips and examined for reactive oxygen species (ROS) production as a marker for oxidative stress. They were loaded for 2 hours with chloromethyl 2',7'-dichlorodihydrofluorescein diacetate (Molecular Probes Inc., Eugene, OR) at a final concentration of 10  $\mu\text{mol/L}$ .<sup>26</sup> Results were expressed as relative fluorescence intensity and normalized to the control cells. In some experiments, ROS was measured after the incubation with tacrolimus or CyA.

### Measurement of Ketone Body Ratio

For the determination of ketone body ratio (KBR), cells were cultured to confluence on a 3.5-cm dish, and the medium was replaced with 700  $\mu\text{l}$  of fresh medium. For arterial KBR, the mice were fasted for >16 hours, followed by the drawing of arterial blood. After a 24-hour incubation, acetoacetate and  $\beta$ -hydroxybutyrate in the medium were measured by monitoring the production or consumption of NADH with a Ketorex kit (Sanwa Chemical, Nagoya, Japan).<sup>27</sup> The KBR was calculated as the acetoacetate/ $\beta$ -hydroxybutyrate ratio.

### Microarray Analysis

An Affymetrix GeneChip analysis cDNA array system (Mouse Genome 430A 2.0, Kurabo, Osaka, Japan) was used for the analysis. Two thousand species of mouse DNA fragments were spotted on the filter. Genes that were 1.5-fold increased or decreased in both of the two tacrolimus-treated mice compared with mice treated with vehicle were defined as up-regulated or down-regulated, respectively.

### Real-Time PCR and Western Blotting

RNA was prepared from mouse liver tissues using TRIzol LS (Invitrogen, Carlsbad, CA). The first-strand cDNAs were synthesized with a first-strand cDNA synthesis kit (Amersham Pharmacia Biotech, Franklin Lakes, NJ). The fluorescent signal was measured with an ABI Prism 7000 system (Applied Biosystems, Tokyo, Japan).

The genes encoding mouse *tumor necrosis factor (TNF)- $\alpha$* , *sterol regulatory element binding protein (SREBP)-1c*, *resistin*, *stearoyl-CoA desaturase (SCD)-1*, and *hypoxanthine phosphoribosyltransferase* were amplified with the primer pairs 5'-GACAAGGTGGGCTACGGGCTTG-3' and 5'-TCCCAAATGGGCTCCCTCT-3', 5'-ACGGAGCCATGG-ATTGCACATTTG-3' and 5'-TACATCTTTAAAGCAGCGG-GTGCCGATGGT-3', 5'-GAAGGCACAGCAGTCTTGA-3' and 5'-GCGACCTGCAGCTTACAG-3', 5'-TTCCCTCTG-CAAGCTCTAC-3' and 5'-CGCAAGAAGGTGCTAAC-GAAC-3', and 5'-CCAGCAAGCTTGCAACCTTAACCA-3' and 5'-GTAATGATCAGTCAACGGGGGAC-3', respec-

tively. The sense and antisense primers were located in different exons to avoid false-positive amplification from contaminated genomic DNA. Each PCR product was confirmed as a single band of the correct size by agarose gel electrophoresis (data not shown).

### Reporter Assay for SREBP-1c Promoter Activity

A plasmid encoding firefly luciferase under the control of the *SREBP-1c* promoter (pGL3-srebp-1cPro) and a control plasmid encoding *Renilla* luciferase (Promega, Madison, WI) were transfected into 293T cells. Tacrolimus was added at a final concentration of 100 nmol/L to the culture medium of 293T cells transfected with pGL3-srebp-1cPro with or without an expression plasmid of HCV core protein at 24 hours after transfection. Cells were harvested 24 hours after treatment. Luciferase activity was measured by using the dual-luciferase reporter assay system (Promega). Firefly luciferase activity was standardized with that of *Renilla* luciferase, and the results are expressed as the fold-increase in relative luciferase units.


### Statistical Analysis

Data are presented as the mean  $\pm$  SE. The significance of the difference in means was determined by a Mann-Whitney *U* test wherever appropriate.  $P < 0.05$  was considered significant.

## Results

### Effect of Tacrolimus on Insulin Resistance Induced by HCV

The *core gene* transgenic mice exhibit insulin resistance in the absence of obesity from the age of 2 months.<sup>16</sup> In tacrolimus-treated mice, there was a slight, but not significant, reduction in body weight compared with control mice at the end of tacrolimus administration at 6 months of age (Figure 1A). Tacrolimus administration to the *core gene* transgenic mice restored the plasma glucose levels to within normal limit (Figure 1B) ( $P < 0.05$ ), whereas it caused no significant reduction in the control mice. The plasma glucose levels in the vehicle-treated *core gene* transgenic mice were higher than those in the *core gene* transgenic mice reported previously,<sup>16</sup> probably owing to the older age of mice in the current study than in the previous one. The levels of serum insulin were also significantly reduced by the treatment with tacrolimus for 3 months in the *core gene* transgenic mice, whereas there was no significant change in the control mice (Figure 1C). The reduction in both plasma glucose and serum insulin levels indicates that the administration of tacrolimus restored the resistance to insulin action, which is attributed to the suppression of insulin action in the liver by the *core* protein.<sup>16</sup> Actually, an insulin tolerance test (1 U/kg b.wt.) demonstrated the improvement of insulin action in the tacrolimus-treated *core gene* transgenic mice (Figure 1D).



**Figure 1.** Effect of tacrolimus (FK506) on glucose and lipid metabolism in the core gene transgenic mice. Tacrolimus (0.1 mg/kg b.wt.) or vehicle was administered to core gene transgenic or control mice i.p., three times weekly for 3 months beginning at 3 months of age. **A:** Body weight at the baseline and end of treatment. **B:** Plasma glucose level. **C:** Serum insulin level. **D:** Insulin tolerance test. Black boxes represent core gene transgenic mice; white boxes represent control mice; gray boxes represent core gene transgenic mice treated with tacrolimus (Tg-FK). **E:** Total lipid content in the liver. **F:** Ratio of oleic/stearic acid [18:1(n-9)/18:0]. **G:** Ratio of palmitoleic/palmitic acid [16:1(n-9)/16:0]. black bars represent transgenic mice; white bars represent control mice. Tg 3 mo indicates 3-month-old transgenic mice showing the baseline state just before FK treatment, and Tg indicates 6-month-old transgenic mice, either with or without tacrolimus treatment for 3 months. Values represent the mean  $\pm$  SE,  $n = 5$  in each group. \* $P < 0.05$ . Tg, transgenic mice; nTg, nontransgenic control mice. \*\* $P < 0.01$ .


### Tacrolimus Improves Lipid Metabolism Disorders in Mice

We then studied whether tacrolimus administration affects lipid metabolism in the mice. The core gene transgenic mice developed a marked hepatic steatosis.<sup>6,14</sup> In addition, the composition of accumulated lipid was different from that in the fatty liver as a result of simple overnutrition: carbon 18 or 16 monounsaturated fatty acid levels were significantly increased.<sup>15</sup> As shown in Figure 1E, the tacrolimus treatment significantly reduced the lipid content in liver tissues compared with the vehicle treatment of the core gene transgenic mice ( $P < 0.05$ ,  $n = 5$  each), whereas there was no change in the control mice. The increased ratios of oleic to stearic acid [18:1(n-9)/18:0] and palmitoleic to palmitic acid [16:1(n-9)/16:0] in the core gene transgenic mice returned to levels similar to those in control mice (Figure 1, F and G) ( $P < 0.05$ ). Thus, the administration of tacrolimus for 3 months restored the abnormalities in lipid metabolism that were induced by the core protein of HCV. Histologically, tacrolimus significantly improved steatosis in the liver of

core gene transgenic mice, in which micro- and macrovesicular lipid droplets were accumulated in hepatocytes, chiefly around the central veins of the liver (Figure 2A). There was no sign of inflammation in the liver with or without the tacrolimus treatment.

### Effect of Tacrolimus on Lipid Metabolism in HepG2 Cells Expressing HCV Core Protein

To further prove the ameliorating effect of tacrolimus on lipid metabolism, we then performed experiments using HepG2 cells that express the core protein.<sup>22,23</sup> HepG2 cells, the lipid metabolism of which is somewhat different from that in normal hepatocytes,<sup>28</sup> show a significant increase in the level of 5,8,11-eicosatrienoic acid [20:3(n-9)], as a result of activations of the fatty acid enzymes,  $\Delta^9$ -,  $\Delta^6$ -, and  $\Delta^5$ -desaturases, by the core protein (H. Miyoshi and K. Koike, unpublished data). Incubation of the core-expressing HepG2 cells with tacrolimus at 100 nmol/L and 1  $\mu$ mol/L for 48 hours significantly reduced the accumulation of 20:3(n-9), whereas CyA treat-



**Figure 2.** Morphological analysis of the liver of the core gene transgenic mice. Representative cases are shown either treated with tacrolimus (FK506) or vehicle (H&E staining). **A:** There is a prominent improvement of steatosis in the 3-month tacrolimus-treated core gene transgenic mice compared with the vehicle-treated mice. **B:** A prominent improvement in steatosis was also obtained by the administration of one-fifth dose of tacrolimus for 1 month beginning at 3 months of age. For histological analysis, two independent researchers evaluated 40 microscopic fields each, and a representative picture is shown for each category. Original magnification,  $\times 125$ . Tg, transgenic mice; nTg, nontransgenic control mice.

ment increased the level of 20:3(n-9) in a dose-dependent manner in the core-expressing HepG2 cells (Figure 3, A and B). Neither tacrolimus nor CyA changed the 20:3(n-9) content in HepG2 cells that do not express the core protein.


*Low Dose of Tacrolimus Also Ameliorates Steatosis and Insulin Resistance*

Because the usual dose of tacrolimus for liver transplantation naturally induces an immunosuppressed state in patients, we conducted a mouse study with a tacrolimus dose lower than that in the aforementioned study. In this low-dose experiment, tacrolimus at 0.02 mg/kg b.wt. (one-fifth of the previous one) was administered to mice for 1 month from the age of 3 months. Similar to the results with the dose of 0.1 mg/kg b.wt., there were significant decreases in the lipid content in the liver ( $9.5 \pm 0.8$  [0.02 mg/kg b.wt. tacrolimus] versus  $18.7 \pm 4.4$  [vehicle only] mg/g liver;  $P < 0.05$ ) and serum insulin concentration ( $96.6 \pm 16.9$  [0.02 mg/kg b.wt. tacrolimus] versus  $1137.1 \pm 88.0$  [vehicle only] pmol/L;  $P < 0.05$ ) in


the core gene transgenic mice treated with tacrolimus. Histological changes are shown in Figure 2B.

*Effect of Tacrolimus on Oxidative Stress and Antioxidative System in Mice*

We next examined whether the 3-month administration of tacrolimus affects the redox state in the core gene transgenic mice. In the liver of the core gene transgenic mice, the ROS level was higher than that in the liver of control mice as determined by lipid peroxidation.<sup>10</sup> Treatment with tacrolimus significantly reduced the level of thiobarbituric acid-reactive substances in the liver of the core gene transgenic mice (Figure 4A) ( $P < 0.05$ ). As a result of oxidative stress overproduction, there was damage in the DNA of hepatocytes of the core gene transgenic mice from a young age.<sup>10</sup> To evaluate the effect of tacrolimus on the nuclear DNA damage, the apurinic/aprimidinic site index was determined in liver tissues from the core gene transgenic mice. As shown in Figure 4B, the apurinic/aprimidinic site index in the liver of the core gene transgenic mice, which was significantly higher



**Figure 3.** Effect of tacrolimus (FK506) or CyA on fatty acid compositions in HepG2 cells expressing the core protein. The fatty acid compositions of the total cell lipids were analyzed, and the percentage of 5,8,11-eicosatrienoic acid [20:3(n-9)] in the core-expressing and control HepG2 cells was calculated. **A:** Treatment with tacrolimus at 0 nmol/L, 100 nmol/L, or 1  $\mu$ mol/L. **B:** Treatment with CyA at 0 nmol/L, 100 nmol/L, or 1  $\mu$ mol/L. Black bars represent core-expressing cells; white bars represent control cells. Because similar results were obtained by using Hep39J, Hep396, and Hep397 cell lines, representative results using the Hep39J cell line are shown. Values represent the mean  $\pm$  SE;  $n = 5$  in each group. \* $P < 0.05$  and \*\* $P < 0.01$ .



**Figure 4.** Effect of tacrolimus (FK506) on oxidative stress in the core gene transgenic mice. Tacrolimus (0.1 mg/kg b.wt.) or vehicle only was administered to the core gene transgenic or control mice for 3 months. **A:** Lipid peroxidation in the liver. **B:** apurinic/aprimidinic (AP) site in the liver as a marker of nuclear DNA damage; **C:** Total glutathione level in the liver. Black bars represent transgenic mice; white bars represent control mice. Tg 3 mo indicates 3-month-old transgenic mice, showing the baseline state just before tacrolimus treatment, and Tg indicates 6-month-old transgenic mice, either with or without 3 months of tacrolimus treatment. Values represent the mean  $\pm$  SE;  $n = 5$  in each group.  $*P < 0.05$ . Tg, transgenic mice; nTg, nontransgenic control mice. TBARS, thiobarbituric acid-reactive substances.

than that in the control mice, was significantly decreased by the tacrolimus treatment to a level similar to that in the control mice ( $P < 0.05$ ).


The level of glutathione, one of the antioxidant systems, was significantly decreased in the liver of the core gene transgenic mice presumably as a result of oxidative stress overproduction but returned to a level similar to that in the control mice after the 3-month administration of tacrolimus, although the difference was not statistically significant ( $P = 0.063$ ) (Figure 4C). Thus, the oxidative stress augmentation induced by the core protein of HCV was reduced by tacrolimus.

#### Effect of Tacrolimus on Oxidative Stress in Core-Expressing HepG2 Cells

Evidence for scavenging ROS by the administration of tacrolimus to the mice prompted us to validate this finding using cultured cells. For this purpose, tacrolimus or CyA was added to the culture medium of HepG2 cells that express or do not express the core protein. After 24 hours of incubation, tacrolimus decreased the ROS production level in the core-expressing HepG2 cells in a dose-dependent manner (Figure 5A). In contrast, no decrease but rather an augmentation of ROS production was observed by the treatment with CyA at various concentrations (Figure 5B).

Because dysfunction of the mitochondrial respiratory chain complex 1 is suspected to be the reason for the ROS production associated with HCV infection (H. Miyoshi and K. Koike, unpublished data),<sup>12,13,17</sup> an increase in the NADH/NAD<sup>+</sup> ratio, which is caused by the repression of the complex 1 NADH dehydrogenase activity, would be a good marker for the mitochondrial complex 1 dys-

function. Therefore, we evaluated the effect of tacrolimus on the accumulation of NADH in the core-expressing HepG2 cells. The NADH/NAD<sup>+</sup> ratio, which is strictly estimated from a reciprocal of KBR,<sup>26,29</sup> was significantly higher in the core gene transgenic mice than in control mice (1/atrial KBR) and in HepG2 cells expressing the core protein than in control cells (1/KBR) (Figure 6A). By the treatment with 1  $\mu$ mol/L tacrolimus, the ratio significantly decreased compared with the baseline (Figure 6B), whereas CyA treatment caused no effect in the core-expressing HepG2 cells (Figure 6C), as was the



**Figure 5.** Effect of tacrolimus (FK506) or CyA on ROS production in HepG2 cells expressing the core protein. Results are expressed as relative brightness and normalized to control cells. **A:** Treatment with tacrolimus at 0 nmol/L, 10 nmol/L, 100 nmol/L, or 1  $\mu$ mol/L. **B:** Treatment with CyA at 0 nmol/L, 10 nmol/L, 100 nmol/L, or 1  $\mu$ mol/L. Black bars represent transgenic mice; white bars represent control cells. Because similar results were obtained by using Hep39J, Hep396, and Hep397 cell lines, representative results using the Hep39J cell line are shown. Values represent the mean  $\pm$  SE;  $n = 5$  in each group.  $*P < 0.05$ ;  $**P < 0.01$ .




case in the determination of ROS by chloromethyl 2',7'-dichlorodihydrofluorescein diacetate.

### Changes in Gene Expression by Tacrolimus Treatment of Mice

We then performed a comprehensive microarray analysis of gene expression in the liver, which was up- or down-regulated by tacrolimus. For this analysis, the tacrolimus-treated mice were compared with the vehicle-treated mice, in two pairs of the core gene transgenic and control mice, respectively. Genes that were 1.5-fold increased or decreased in both of the two tacrolimus-treated mice

compared with those treated with vehicle were defined as up-regulated or down-regulated, respectively. As shown in Table 1, several genes were found to be up-regulated or down-regulated in both the core gene transgenic and control mice after the treatment with tacrolimus for 3 months. A number of genes including that for TNF- $\alpha$  were up- or down-regulated both in the core gene transgenic and control mice. In contrast, the expressions of some genes including that for resistin were differentially regulated between the core gene transgenic and control mice. The expressions of these genes were confirmed by real-time PCR analysis.

Then, to explore the mechanism by which tacrolimus reverses the pathological effect of the core protein in the liver, we examined, by real-time PCR analysis, the expression of some cellular genes including TNF- $\alpha$ , SREBP-1c, SCD-1, and proteasome activator 28- $\gamma$ . These genes or gene products have been suggested to play a pivotal role in the pathogenesis of HCV-associated liver disease.<sup>30,31</sup> TNF- $\alpha$  and SREBP-1c genes have been shown to be up-regulated in the liver of the core gene transgenic mice and considered to play a role in the development of insulin resistance and steatosis.<sup>30,31</sup> By the treatment of the core gene transgenic mice with tacrolimus for 3 months, there was a significant decrease in the mRNA level of both TNF- $\alpha$  and SREBP-1c (Figure 7, A–C) ( $P < 0.05$ ). The SCD-1 mRNA level was also reduced in the tacrolimus-treated core gene transgenic mice. Because down-regulation of SREBP-1c expression by tacrolimus was observed only in the core gene transgenic mice but not in control mice, it is estimated that tacrolimus antagonizes the action of core protein in its transactivating function of the SREBP-1c promoter. The down-regulation of SREBP-1c, then, would lead to the suppression of SCD-1 expression and amelioration of steatosis. We confirmed this by conducting luciferase assays using cultured cells. As shown in Figure 7D, tacrolimus cancelled the effect of the core protein on the activation of SREBP-1c gene promoter. The level of the proteasome activator 28- $\gamma$  protein, which is indispensable for the action of the core protein in the pathogenesis of HCV-associated liver lesion,<sup>31</sup> was determined by Western blotting, but there was no change caused by the tacrolimus treatment (data not shown).



### Discussion

Antiviral treatment for chronic hepatitis C has advanced markedly. Nearly 50% of patients with chronic hepatitis C

**Figure 6.** Effect of tacrolimus (FK506) or CyA on NADH accumulation in HepG2 cells expressing the core protein. **A:** NADH/NAD<sup>+</sup> was determined in mice (left) or HepG2 cells (right) with or without the core protein. **B:** The ketone body ratio was determined in HepG2 cells with or without the core protein after incubation with tacrolimus for 24 hours at 0 nmol/L, 10 nmol/L, 100 nmol/L, or 1  $\mu$ mol/L. **C:** The ketone body ratio was determined in HepG2 cells with or without the core protein after incubation with CyA for 24 hours at 0 nmol/L, 10 nmol/L, 100 nmol/L, or 1  $\mu$ mol/L. Black bars represent transgenic mice; white bars represent control cells. Because similar results were obtained by using Hep39J, Hep396 and Hep397 cell lines, representative results using the Hep39J cell line are shown. Values represent the mean  $\pm$  SE;  $n = 5$  in each group. \* $P < 0.05$ . AKBR, arterial KBR; Tg, transgenic mice; nTg, nontransgenic mice.

**Table 1.** Genes Whose Expression Levels in the Mouse Liver Were Altered by the Treatment with FK506

	Up-regulated in Tg	Down-regulated in Tg
Up-regulated in nTg	Nuclear factor, erythroid derived 2 DNA segment, human D6S2654E Fatty acid binding protein 5 epidermal squalene epoxidase Zinc finger protein 69	Resistin Resistin like alpha Nuclear receptor subfamily 4, group A, member insulin-like growth factor binding protein 1 calcium and integrin binding family member 3
Down-regulated in nTg	X-linked lymphocyte-regulated 4 Cytochrome P450, family 2, subfamily b, polypeptide 9 X-linked lymphocyte-regulated 3a Signal sequence receptor, delta	Tumor necrosis factor alpha Cytochrome P450, family 17, subfamily a, polypeptide 1 B-cell leukemia/lymphoma 6

Genes with altered expression in Tg (columns) or in nTg (rows) are described in a 4 × 4 table. Genes that were 1.5-fold increased or decreased in both of the two FK506-treated mice compared with those treated with placebo were defined as up-regulated or down-regulated, respectively. Tg, core gene transgenic mouse; nTg, nontransgenic control mouse.


with HCV genotype 1 and high viral loads achieve a sustained virological response as a result of ribavirin/peginterferon combination therapy.<sup>32,33</sup> However, the remaining patients who could not achieve sustained virological response continue to experience progression of chronic hepatitis and have a high probability for development of HCC. Although therapies with new agents such as viral protease or RNA polymerase inhibitors are being developed, there is hope for development of the means to retard the progression of chronic hepatitis.

Recently, evidence showing that hepatic steatosis and insulin resistance are crucial determinants of the progression of liver fibrosis has accumulated.<sup>34–37</sup> Moreover, the importance of oxidative stress, which is closely associated with metabolic disorders such as insulin resistance and steatosis, is implicated in the pathogenesis of HCV-associated liver disease. Given the suggested association of oxidative stress augmentation with the dysfunction of mitochondrial respiration in HCV infection,<sup>12,13,17</sup> one possibility to ameliorate such a condition is the use of agents that can protect the mitochondrial respiratory function. Tacrolimus is one such agent with evidence of providing protection of the mitochondrial respiratory function,<sup>18–21</sup> although it does not show an antiviral effect.

In the current study, the administration of tacrolimus significantly improved the disturbances in lipid and glucose metabolism both *in vivo* and *in vitro*. As disorders of

lipid metabolism associated with HCV infection, hepatic steatosis and increases in monounsaturated fatty acid levels have been demonstrated.<sup>3,4,6,7,15</sup> The latter is caused by the activation of fatty acid enzymes such as  $\Delta^9$ - or  $\Delta^6$ -desaturase, resulting in increases in 18:1(n-9)/18:0 and 16:1(n-9)/16:0 ratios (H. Miyoshi and K. Koike, unpublished data).<sup>15</sup> Tacrolimus ameliorated these lipid alterations associated with HCV infection with no impact on mouse body weight. Tacrolimus also improved the insulin resistance in the HCV mouse model, in which tyrosine phosphorylation of insulin receptor substrate-1 is impaired by the HCV core protein.<sup>16</sup>

Moreover, tacrolimus treatment ameliorated oxidative stress augmentation, which is considered to play a pivotal role in the progression of liver disease or the development of HCC in HCV infection.<sup>10–13</sup> In mice transgenic for the HCV core gene, in which DNA damage develops because of oxidative stress augmentation,<sup>13</sup> tacrolimus decreased the levels of peroxylipid and DNA damage formations. Dysfunction of the mitochondrial respiratory chain complex 1 is suspected to be a source of ROS overproduction in HCV infection.<sup>12,13,17</sup> To assess changes in mitochondrial complex 1 function caused by tacrolimus, the NADH/NAD<sup>+</sup> ratio, which reflects the complex 1 NADH dehydrogenase activity, was determined in HepG2 cells expressing the core protein. The NADH/NAD<sup>+</sup> ratio, which is strictly estimated from a reciprocal of KBR (1/atrial KBR),<sup>26,29</sup> was significantly re-



**Figure 7.** A–C: Effect of tacrolimus (FK506) on mRNA levels of cellular genes. The mRNA levels of TNF- $\alpha$  (A), SREBP-1c (B), and SCD-1 (C) genes were determined by real-time PCR analysis in the tacrolimus- or vehicle-treated mouse livers. The transcriptions of the genes were normalized with that of hypoxanthine phosphoribosyltransferase, and the values are expressed as relative activities. D: Effect of tacrolimus on the transactivating function of the core protein on the SREBP-1c promoter. A luciferase assay was performed using a plasmid encoding firefly luciferase under the control of the SREBP-1c promoter with or without the expression of HCV core protein. Tacrolimus was added at a final concentration of 100 nmol/L to the culture medium. Black bars represent transgenic mice; white bars represent control cells. Values represent the mean  $\pm$  SE;  $n = 5$  in each group. \* $P < 0.05$ . Tg, transgenic mice; nTg, nontransgenic mice.

duced by the addition of tacrolimus but not CyA. Thus, tacrolimus protected the mitochondrial respiratory chain complex 1 function from the impact of the core protein, decreased oxidative stress, and improved steatosis and insulin resistance.

Some of features induced by the core protein including steatosis, insulin, and DNA damage were already present in the core gene transgenic mice at 3 months of age as the baseline, and those were improved by tacrolimus treatment. This fact indicates that tacrolimus is not only preventing the development of core-induced features but also reversing such changes in the mouse liver.

The tacrolimus dose used in the current study was 0.1 mg/kg b.wt. This is the same dose as that used in recipients of liver or kidney transplantation. The result of a subexperiment with a lower tacrolimus dose of 0.02 mg/kg b.wt. was similar to that with the dose of 0.1 mg/kg b.wt. This finding is promising because it indicates that the "anti-core protein effect" may be achievable at such a low dose of tacrolimus without provoking strong immunosuppression. The tacrolimus concentration (100 nmol/L) that caused the anti-core protein effect in the cultured cell study is similar to that in the blood of recipients of liver transplantation and much lower than those used in previous studies.<sup>19,38</sup> In the current study, tacrolimus was administered only i.p., although it tacrolimus is administered i.v. or p.o. in humans. Therefore, a concern may arise regarding the administration route. Because the bioavailability of tacrolimus is approximately 25% (range from 5 to 93%) in human patients,<sup>39</sup> a difference in the concentrations of tacrolimus may be possible between i.p. and p.o. administration. However, in human patients, target levels of tacrolimus concentration are generally achieved by p.o. administration as the maintenance therapy. Therefore, the target concentration would be achieved in mouse models by p.o. administration for 3 months as it is in human patients. Our current results strongly support the notion that tacrolimus can protect the mitochondrial respiratory function, resulting in a reduction of ROS production.

There is also a controversy concerning the effect of tacrolimus on glucose homeostasis. Post-transplantation diabetes is a complication in kidney or liver transplantation.<sup>40,41</sup> *In vivo* and *in vitro* studies have shown that tacrolimus may inhibit insulin secretion from the pancreatic  $\beta$ -cells.<sup>40</sup> Thus, tacrolimus may have a potential to induce diabetes. However, there have been no well designed studies on this specific point: in one study, corticosteroid withdrawal from tacrolimus-based immunosuppression reduced insulin resistance without changing insulin secretion.<sup>41</sup> In our study using the HCV mouse model, tacrolimus administration at the dose similar to those in organ transplant recipients decreased serum insulin levels without increasing plasma glucose levels. These results point toward the future use of tacrolimus *in vivo* for the amendment of metabolic abnormalities, such as steatosis and insulin resistance, associated with HCV infection. However, it should be noted that there is a difference between our mouse model and human patients. Organ transplant recipients generally have injury to other bodily organs after a prolonged course of illness,

whereas the mouse model we have exploited does not. In addition, our mouse model originally has insulin resistance with the presence of hyperplasia of Langerhans islands.<sup>16</sup> Therefore, the effect of tacrolimus on glucose homeostasis in the current mouse study may not be exactly applicable to human patients.

The results of the gene expression analysis by microarray and subsequent real-time PCR were of considerable interest. Tacrolimus reduced the mRNA levels of TNF- $\alpha$ , SCD-1, and SREBP-1c genes, which are elevated in both patients with chronic hepatitis C and HCV core gene transgenic mice.<sup>30,31</sup> The elevation in the TNF- $\alpha$  level causes insulin resistance *in vivo*, which is also observed in HCV core gene transgenic mice.<sup>16</sup> The elevations in SREBP-1c and SCD-1 gene mRNA levels cause the overproduction of triglycerides, leading to the development of steatosis. The reductions in the expression levels of these genes may explain the effect of tacrolimus on the improvement of steatosis, insulin resistance, and oxidative stress in these HCV models. Although recent investigations have shown that the immunosuppressive drugs tacrolimus and rapamycin inhibit the expression of different inflammatory mediators,<sup>42,43</sup> the anti-inflammatory functions of these drugs are not well established. Our *in vitro* and *in vivo* experiments confirmed that tacrolimus inhibited the induction of ROS generation, which is mediated by the core protein. Our data indicate that the inhibition of ROS formation may explain part of the favorable effect of immunosuppressive agents on inflammatory conditions.

In conclusion, our results demonstrate that tacrolimus has protective potential against damage caused by the HCV core protein including the induction of steatosis, insulin resistance, and oxidative stress, both in mice and cultured cells. Although more studies are required to elucidate the precise mechanism underlying the potential of tacrolimus in reversing the pathogenesis in HCV infection, these results may provide new therapeutic tools for chronic hepatitis C, in which oxidative stress and abnormalities in lipid and glucose metabolism contribute to liver pathogenesis.

## References

1. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, Watanabe Y, Koi S, Onji M, Ohta Y, Choo Q, Houghton M, Kuo G: Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. *Proc Natl Acad Sci USA* 1990, 87:6547-6549
2. Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L, Fiorentino G, Craxi A, Ciccaglione A, Giuseppetti R, Stroffolini T, Pagliaro L: Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. *Ann Intern Med* 1992, 116:97-102
3. Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM: The pathology of chronic hepatitis C. *Hepatology* 1992, 15:567-571
4. Bach N, Thung SN, Schaffner F: The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. *Hepatology* 1992, 15:572-577
5. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Bréchet C: Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. *Proc Natl Acad Sci USA* 1997, 94:1200-1205
6. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K: Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. *J Gen Virol* 1997, 78:1527-1531

7. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, Gosert R, Xiao SY, Weinman SA, Lemon SM: Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. *Gastroenterology* 2002, 122:352–365
8. Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J, O'Rahilly S, Shore S, Tom BD, Alexander GJ: Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. *Hepatology* 1999, 30:1059–1063
9. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. *Ann Intern Med* 2000, 133:592–599
10. Choi J, Ou JH: Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. *Am J Physiol Gastrointest Liver Physiol* 2006, 290:G847–G851
11. Koike K, Miyoshi H: Oxidative stress and hepatitis C viral infection. *Hepatology* 2006, 34:65–76
12. Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J, Weinman SA: Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. *J Biol Chem* 2005, 280:37481–37488
13. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Miyamura T, Kimura S, Koike K: Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. *Cancer Res* 2001, 61:4365–4370
14. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Matsuura Y, Kimura S, Miyamura T, Koike K: The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *Nat Med* 1998, 4:1065–1067
15. Moriya K, Todoroki T, Tsutsumi T, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Takayama T, Makuuchi M, Watanabe K, Miyamura T, Kimura S, Koike K: Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans. *Biophys Biochem Res Commun* 2001, 281:1207–1212
16. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Kimura S, Moriya K, Koike K: Hepatitis C virus and diabetes: direct involvement of the virus in the development of insulin resistance. *Gastroenterology* 2004, 126:840–848
17. Piccoli C, Scrima R, Quarato G, D'Aprile A, Ripoli M, Lecce L, Boffoli D, Moradpour D, Capitanio N: Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. *Hepatology* 2007, 46:58–65
18. Cetinkale O, Konukoğlu D, Senel O, Kemerli GD, Yazar S: Modulating the functions of neutrophils and lipid peroxidation by FK506 in a rat model of thermal injury. *Burns* 1999, 25:105–112
19. Kaibori M, Inoue T, Tu W, Oda M, Kwon AH, Kamiyama Y, Okumura T: FK506, but not cyclosporin A, prevents mitochondrial dysfunction during hypoxia in rat hepatocytes. *Life Sci* 2001, 69:17–26
20. Keswani SC, Chander B, Hasan C, Griffin JW, McArthur JC, Hoke A: FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. *Ann Neurol* 2003, 53:57–64
21. Kaymaz M, Emmez H, Bukan N, Dursun A, Kurt G, Paçsaoğlu H, Paçsaoğlu A: Effectiveness of FK506 on lipid peroxidation in the spinal cord following experimental traumatic injury. *Spinal Cord* 2005, 43:22–26
22. Ruggieri A, Murdolo M, Harada T, Miyamura T, Rapicetta M: Cell cycle perturbation in a human hepatoblastoma cell line constitutively expressing hepatitis C virus core protein. *Arch Virol* 2004, 149:61–74
23. Aizaki H, Harada T, Otsuka M, Seki N, Matsuda M, Li YW, Kawakami H, Matsuura Y, Miyamura T, Suzuki T: Expression profiling of liver cell lines expressing entire or parts of hepatitis C virus open reading frame. *Hepatology* 2002, 36:1431–1438
24. Todoroki T, Imai K, Matsumoto K, Kano S: Initial deactivation of Florisil adsorbent for column chromatographic separation of lipids. *Analyst* 1983, 108:1267–1269
25. Morrison WR, Smith LM: Preparation of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride-methanol. *J Lipid Res* 1964, 5:600–608
26. Gelasco AK, Raymond JR: Indoxyl sulfate induces complex redox alterations in mesangial cells. *Am J Physiol Renal Physiol* 2006, 290:F1551–F1558
27. Williamson DH, Mellanby J, Krebs HA: Enzymic determination of D(-)-β-hydroxybutyric acid and acetoacetic acid in blood. *Biochem J* 1962, 82:90–96
28. Choi Y, Park Y, Pariza MW, Ntambi JM: Regulation of stearoyl-CoA desaturase activity by the *trans*-10,*cis*-12 isomer of conjugated linoleic acid in HepG2 cells. *Biochem Biophys Res Commun* 2001, 284:689–693
29. Williamson DH, Lund P, Krebs HA: The redox state of free nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver. *Biochem J* 1967, 103:514–527
30. Tsutsumi T, Suzuki T, Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Matsuura Y, Kimura S, Koike K, Miyamura T: Intrahepatic cytokine expression and AP-1 activation in mice transgenic for hepatitis C virus core protein. *Virology* 2002, 304:415–424
31. Moriishi K, Mochizuki R, Moriya K, Miyamoto H, Mori Y, Abe T, Murata S, Tanaka K, Suzuki T, Miyamura T, Koike K, Matsuura Y: Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. *Proc Natl Acad Sci USA* 2007, 104:1661–1666
32. Hoofnagle JH, Seeff LB: Peginterferon and ribavirin for chronic hepatitis C. *N Engl J Med* 2006, 355:2444–2451
33. Koike K: Antiviral treatment of hepatitis C: present status and future prospects. *J Infect Chemother* 2006, 12:227–232
34. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utlili R, Ruggieri G: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology* 2001, 33:1358–1364
35. Patton HM, Patel K, Behling C, Tripodi MF, Utlili R, Ruggieri G: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. *J Hepatol* 2004, 40:484–490
36. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J: Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. *Gastroenterology* 2003, 125:1695–1704
37. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, Jonsson JR: Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. *J Hepatol* 2003, 39:1042–1048
38. Han SY, Chang EJ, Choi HJ, Kwak CS, Suh SI, Bae JH, Park SB, Kim HC, Mun KC: Effect of tacrolimus on the production of oxygen free radicals in hepatic mitochondria. *Transplant Proc* 2006, 38:2242–2243
39. Staatz CE, Tett SE: Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. *Clin Pharmacokinet* 2004, 43:623–653
40. Penforinis A, Kury-Paulin S: Immunosuppressive drug-induced diabetes. *Diabetes Metab* 2006, 32:539–546
41. van Hooff JP, Christiaans MH, van Duijnhoven EM: Evaluating mechanisms of post-transplant diabetes mellitus: *Nephrol Dial Transplant* 2004, 19(Suppl 6):vi8–vi12
42. Vigil SV, de Liz R, Medeiros YS, Fröde TS: Efficacy of tacrolimus in inhibiting inflammation caused by carrageenan in a murine model of air pouch. *Transpl Immunol* 2008, 19:25–29
43. Pereira R, Medeiros YS, Fröde TS: Antiinflammatory effects of tacrolimus in a mouse model of pleurisy. *Transpl Immunol* 2006, 16:105–111